期刊文献+

以肾病综合征为首发表现的小细胞肺癌一例报告 被引量:1

原文传递
导出
摘要 1病例报告 患者,男,6l岁,因“眼睑及双下肢水肿6个月,胸闷5个月”于2010-04-19入我院。患者人院前6个月无明显诱因出现眼睑及双下肢水肿,于外院住院诊治,化验尿蛋白+++,血白蛋白22g/L,行肾穿刺活检术,确诊为肾病综合征、膜性肾病Ⅱ期,给予泼尼松口服50mg/d及其他对症治疗,水肿有所减轻,但蛋白尿无缓解;5个月前患者出现胸闷、憋气,偶有咳嗽,多为干咳,无胸痛、咯血,症状逐渐加重,为进一步诊治而入我院。入院查体:T:36.0℃,BP:120/80mmHg,神志清,呼吸平稳,眼呛水肿,浅表淋巴结无肿大,双肺呼吸音清,心律齐,肝脾不大,双下肢中度凹陷性水肿。
作者 张晓宁
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第20期1590-1590,1592,共2页 Chinese Journal of Cancer Prevention and Treatment
  • 相关文献

参考文献9

  • 1Galloway J. Remarks on hodgkin' s disease[J]. Br Med J, 1922,2 (3234) :1201-1208.
  • 2Bacchetta J, Juillard L, Cochat P, et al. Paraneoplastic glomerular diseases and malignancies [J ]. Cri Rev Oncol Hematol, 2009, 70(1) :39-58.
  • 3Audard V, Larousserie F, Grimbert P, et al. Minimal change ne- phrotic syndrome and classical Hodgkin' s lymphoma: Report of 21 cases and review of the literature[J]. Kidney Int, 2006, 69(12) :2251-2260.
  • 4Mimura I, Tojo A, Kinugasa S, et al. Renal cell carcinoma in asso- ciation with IgA nephropathy in the elderly[J]. Am J Med Sci, 2009,338(5) :431-432.
  • 5Lee JC, Yamauchi H, Hopper JJr. The association of cancer and the nephrotic syndrome[J]. Ann Intern Med, 1996,64 ( 1 ) : 41-45.
  • 6de Oliveira Filgueira PH,Vasconcelos LF,da Silva GB,et al. Para- neoplastic syndromes and the kidney [J].Saudi J Kidney Dis Transpl,2010,21(2) :222-231.
  • 7吴辉塔,陈元.霍奇金淋巴瘤继发肾病综合征1例诊治分析[J].中国误诊学杂志,2008,8(4):991-992. 被引量:1
  • 8牛红心,龙海波,周伟东,朱艳,李申恒.实体肿瘤相关肾小球病临床特征分析[J].广东医学,2011,32(22):2959-2961. 被引量:3
  • 9Ohara G, Satoh H, Kurishima K. Paraneoplastic nephrotic syn drome in patients with lung eancer[J].Intern Med,2009,48(20) :1817-1820.

二级参考文献15

  • 1LEFAUCHEUR C, STENGEL B, NOCHY D, et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association [ J ]. Kidney Int, 2006, 70 ( 8 ) : 1510 -1517.
  • 2SCHILLINGER F, MILCENT T, WOLF C, et al. Nephrotie syndrome as the presenting feature of malignant thymoma[ J]. Nephrol Dial Transplant, 1997, 12(12) : 2732 -2734.
  • 3CULLIS B, D'SOUZA R, SIMPSON R, et al. Bilateral collectingduct carcinoma presenting with turnout associated nephritis and end-stage renal failure. A case report and review of tlae literature [J]. Int Urol Nephrol, 2004, 36(1) : 11 -14.
  • 4KIM Y T, RHA S Y, SHIM C Y, et al. A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma[ J ]. Yonsei Med J, 2003, 44(3) : 539 -543.
  • 5LOI S, PERRY G J, STANDISH H, et al. Glomerulosclerosis: aparaneoplastic phenomenon? [J]. Nephrology (Carlton), 2004, 9(6) : 387 -391.
  • 6WERNER T L, AGARWAL N, CARNEY H M, et al. Management of cancer-associated thrombotic microangiopathy: What is the right approach? [J]. Am J Henatol, 2007, 82(4) : 295-298.
  • 7BACCHETTA J, JUILLARD L, COCHAT P, et al. Paraneoplastic glomerular diseases and malignancies [ J ]. Crit Rev Oncol Hematol, 2009, 70(1): 39-58.
  • 8DABBS D J, STRIKER L M, MIGNON F, et al. Glomerular lesions in lymphomas and leukemias [ J ]. Am J Med, 1986, 80 (1) : 63 -70.
  • 9DE OLIVEIRA FILGUEIRA P H, VASCONCELOS L F, DA SILVA G B, et al. Paraneoplastic syndromes and the kidney [ J ]. Saudi J Kidney Dis Transpl, 2010, 21(2) : 222 -231.
  • 10PUOLIJOKI H, MUSTONEN J, PETTERSSON E, et al. Proteinuria and haematuria are frequently present in patients with lung cancer[ J ]. Nephrol Dial Transplant, 1989, 4 ( 11 ) : 947-950.

共引文献2

同被引文献9

  • 1B. Hanfstein,M. C. Mueller,R. Hehlmann.Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia . 2012
  • 2Hoang Tien,Dahlberg Suzanne E,Sandler Alan B,Brahmer Julie R,Schiller Joan H,Johnson David H.Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2012
  • 3Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, The . 2004
  • 4Itzykson R,Kosmider O,Cluzeau T,Mansat-De Mas V,Dreyfus F,Beyne-Rauzy O,Quesnel B,Vey N,Gelsi-Boyer V,Raynaud S,Preudhomme C,Adès L,Fenaux P,Fontenay M.Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K . 2011
  • 5Fairclough DL.Design and analysis of quality of life studies in clinical trials. . 2012
  • 6孙燕,吴一龙,李龙芸,廖美琳,蒋国梁,EdwardS. Kim,Jean-YvesDouillard,Tsveta Milenkova.吉非替尼或多西他赛治疗一线化疗失败的非小细胞肺癌的临床分析[J].中华肿瘤杂志,2011,33(5):377-380. 被引量:25
  • 7李小优,吴建中,曹海霞,吴剑秋,冯继锋.5-aza-CdR增强吉非替尼对人非小细胞肺癌细胞株H1650敏感性机制的研究[J].中华肿瘤防治杂志,2012,19(6):423-427. 被引量:2
  • 8高玉堂.肿瘤预防和肿瘤流行病学研究中的若干问题[J].中华肿瘤杂志,2012,34(7):554-556. 被引量:7
  • 9岳金波,王真真,于金明.ⅢA期非小细胞肺癌术后治疗研究现状[J].中华肿瘤防治杂志,2013,20(20):1614-1618. 被引量:11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部